



Marksans Pharma Ltd.

August 18, 2025

BSE Limited

Corporate Relation Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400001.

Scrip Code: 524404

National Stock Exchange of India Limited

Listing Department
Exchange Plaza, C-1, Block-G,
Bandra-Kurla Complex,
Bandra (East), Mumbai - 400051.

Symbol: MARKSANS

Sub: Press Release

Marksans Pharma Limited's wholly owned subsidiary in UK, Relonchem Limited receives Marketing Authorization for its products.

Marksans Pharma Limited (Reuters: MARK.BO; Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 524404) hereby announces that its wholly owned subsidiary Relonchem Limited in UK has received Marketing Authorization for the below-mentioned products from UK MHRA:

1. Metformin Hydrochloride Relonchem 500 mg Prolonged Release Tablets
2. Metformin Hydrochloride Relonchem 750 mg Prolonged Release Tablets
3. Metformin Hydrochloride Relonchem 1000 mg Prolonged Release Tablets

For Marksans Pharma Limited

Harshavardhan Panigrahi
Company Secretary

About Marksans Pharma Ltd

Marksans Pharma Limited (www.marksanspharma.com) headquartered at Mumbai, India is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets. The company's manufacturing facilities located in India, USA and UK are approved by several leading regulatory agencies including USFDA, UKMHRA and Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, Anti-diabetic, Pain Management, Gastroenterological and Anti-allergies. The company is marketing these products globally.

Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara,
Andheri (W), Mumbai - 400 053 Tel.: +91 22 4001 2000 E-mail: info@marksanspharma.com
www.marksanspharma.com